Thursday, February 17, 2011

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

The meta-analysis concluded that the prophylactic use of glucagon-like peptide-1 receptor agonists for type 2 diabetes effectively reduced glycosylated haemoglobin and postprandial glucose; it had a similar effect to insulin in patients unresponsive to sulphonylurea or metformin. The safety profile was reassuring.